2 weeks Ago
Emergent BioSolutions Inc. ( NYSE: EBS ) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Frank Vargo – Assistant Treasurer Joe Papa – President and Chief Executive Officer Rich Lindahl – Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Brandon Fox – Brodmann and Renshaw Operator Thank you for standing by. My name is Kris and I will be your conference operator today.
At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I would now like to turn the call over to Frank Vargo, Assistant Treasurer.
Please go ahead. Frank Vargo Good afternoon everyone. Thank you for joining today as Emergent is discussing their operational and financial results for the third quarter 2024.
As is customary, today's call is open to all participants, is being recorded and is copyrighted by Emergent BioSolutions. In addition to today's press release, a slide presentation accompanying this webcast is available to all webcast participants. Turning to Slide 3.
During today's call, Emergent may make projections and other forward-looking statements related to their business, future events, their prospects, or future performance. These forward-looking statements are based on their current intentions, beliefs and expectations regarding future events. Any forward-looking statement speaks only as of the date of this call and except as required by law, Emergent does not undertake to update any forward-looking statements to reflect new information, events or circumstances.
Investors should consider this cautionary statement as well as the risk factors identified in Emergent's periodic reports filed with the SEC when evaluating their forward-looking statements. During today's call, Emergent may also discuss certain non-GAAP financial.
